Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes

[1]  A. Karsan,et al.  Correlation of clinical response and response duration with miR-145 induction by lenalidomide in CD34+ cells from patients with del(5q) myelodysplastic syndrome , 2013, Haematologica.

[2]  G. Mufti,et al.  TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis , 2013, British journal of haematology.

[3]  J. Clark,et al.  Lenalidomide promotes p53 degradation by inhibiting MDM2 auto-ubiquitination in myelodysplastic syndrome with chromosome 5q deletion , 2013, Oncogene.

[4]  A. Glasmacher,et al.  Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis , 2012, Leukemia.

[5]  J. Gribben,et al.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. , 2012, Blood.

[6]  A. List,et al.  Lenalidomide for treatment of myelodysplastic syndromes. , 2012, Current pharmaceutical design.

[7]  A. Jankowska,et al.  Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Chevret,et al.  Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies , 2012, Haematologica.

[9]  R. Schlenk,et al.  Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study , 2012, Leukemia.

[10]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[11]  D. Neuberg,et al.  Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis , 2011, Blood.

[12]  Eva Hellström-Lindberg,et al.  TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Fenaux,et al.  58 Interaction of karyotype complexity and response on overall survival and AML progression in lenalidomide-treated Low/INT-1 risk del (5q) MDS patients , 2011 .

[14]  J. Kutok,et al.  Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. , 2011, Blood.

[15]  E. Padron,et al.  Biology and treatment of the 5q- syndrome , 2011, Expert review of hematology.

[16]  P. Fenaux,et al.  Cytogenetic follow-up by karyotyping and fluorescence in situ hybridization: implications for monitoring patients with myelodysplastic syndrome and deletion 5q treated with lenalidomide , 2011, Haematologica.

[17]  C. Steidl,et al.  Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.

[18]  A. McKenzie,et al.  Advances in the 5q- syndrome. , 2010, Blood.

[19]  R. Latagliata,et al.  Increases In Mirna-145 and Mirna-146a Expression In Patients with IPSS Lower-Risk Myelodysplastic Syndromes and Del(5q) Treated with Lenalidomide. , 2010 .

[20]  R. Chopra,et al.  Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes , 2010, Expert review of anticancer therapy.

[21]  L. Trümper,et al.  FISH analysis of circulating CD34+ cells as a new tool for genetic monitoring in MDS: verification of the method and application to 27 MDS patients. , 2010, Leukemia research.

[22]  P. Woll,et al.  Persistent malignant stem cells in del(5q) myelodysplasia in remission. , 2010, The New England journal of medicine.

[23]  R. Latagliata,et al.  Changes in RPS14 expression levels during lenalidomide treatment in Low‐ and Intermediate‐1‐risk myelodysplastic syndromes with chromosome 5q deletion , 2010, European journal of haematology.

[24]  M. Laouri,et al.  Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Tefferi,et al.  WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations , 2010, Leukemia.

[26]  M. L. Le Beau,et al.  Haploinsufficiency of Apc leads to ineffective hematopoiesis. , 2010, Blood.

[27]  David A. Williams,et al.  The Apc(min) mouse has altered hematopoietic stem cell function and provides a model for MPD/MDS. , 2010, Blood.

[28]  B. Ebert,et al.  Ribosomopathies: human disorders of ribosome dysfunction. , 2010, Blood.

[29]  S. Pileri,et al.  Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. , 2010, Blood.

[30]  P. Korkolopoulou,et al.  Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion , 2010, Haematologica.

[31]  M. Jädersten.  Pathophysiology and treatment of the myelodysplastic syndrome with isolated 5q deletion , 2010, Haematologica.

[32]  Y. Tohyama,et al.  Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis , 2010, Leukemia.

[33]  A. Warren,et al.  A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q− syndrome , 2009, Nature Medicine.

[34]  Ryan D. Morin,et al.  Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype , 2010, Nature Medicine.

[35]  E. Hellström-Lindberg,et al.  Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression , 2010, Annals of Hematology.

[36]  H. Kreipe,et al.  Anti-Angiogenic in-Vivo Effect of Lenalidomide and Its Impact On Neoplastic and Non-Neoplastic Hematopoiesis in MDS with Del(5q) Chromosome Abnormality. , 2009 .

[37]  J. Issa,et al.  The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities , 2009, Cancer.

[38]  Karl J. Dykema,et al.  5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics , 2009, Oncogene.

[39]  G. Prendergast,et al.  Loss of RhoB Expression Enhances the Myelodysplastic Phenotype of Mammalian Diaphanous-Related Formin mDia1 Knockout Mice , 2009, PloS one.

[40]  J. Byrd,et al.  A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomide , 2009, Proceedings of the National Academy of Sciences.

[41]  Lei Wu,et al.  The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions. , 2009, Microvascular research.

[42]  J. Maciejewski,et al.  Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  P. Schafer,et al.  Direct Inhibitory Effects of Lenalidomide on the Proliferation and VEGF Production of Non-Hodgkin Lymphoma Cells Are Associated with Increased SPARC Expression , 2008 .

[44]  S. Nimer,et al.  Myelodysplastic syndromes: diagnosis and staging. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[45]  H. Dombret,et al.  Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. , 2008, Leukemia research.

[46]  J. Clohessy,et al.  Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. , 2008, Blood.

[47]  T. Golub,et al.  Identification of RPS14 as a 5q- syndrome gene by RNA interference screen , 2007, Nature.

[48]  Thomas H Müller,et al.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. , 2007, Blood.

[49]  M. Cazzola,et al.  Gene expression profiling of CD34+ cells in patients with the 5q− syndrome , 2007, British journal of haematology.

[50]  K. Eisenmann,et al.  Myeloproliferative defects following targeting of the Drf1 gene encoding the mammalian diaphanous related formin mDia1. , 2007, Cancer research.

[51]  S. Lehmann,et al.  Common deleted genes in the 5q− syndrome: thrombocytopenia and reduced erythroid colony formation in SPARC null mice , 2007, Leukemia.

[52]  B. Sander,et al.  Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients , 2007, Proceedings of the National Academy of Sciences.

[53]  A. Beggs,et al.  Ribosomal protein S24 gene is mutated in Diamond-Blackfan anemia. , 2006, American journal of human genetics.

[54]  S. Green,et al.  Lenalidomide: targeted anemia therapy for myelodysplastic syndromes. , 2006, Cancer control : journal of the Moffitt Cancer Center.

[55]  P. Greenberg,et al.  Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. , 2006, The New England journal of medicine.

[56]  M. Cazzola,et al.  Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. , 2006, Haematologica.

[57]  J. Bennett,et al.  Anti-Angiogenic In Vivo Effect of Lenalidomide (CC-5013) in Myelodysplastic Syndrome with del(5q) Chromosome Abnormality and Its Relation to the Course of Disease. , 2005 .

[58]  Luca Malcovati,et al.  Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  B. Dimitrov,et al.  Hemoglobin level threshold for cardiac remodeling and quality of life in myelodysplastic syndrome. , 2005, Leukemia research.

[60]  L. Rimsza,et al.  Efficacy of lenalidomide in myelodysplastic syndromes. , 2005, The New England journal of medicine.

[61]  A. Dalgleish,et al.  Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects , 2002, British Journal of Cancer.

[62]  N. Harris,et al.  The World Health Organization (WHO) classification of the myeloid neoplasms. , 2002, Blood.

[63]  A. Kasprzyk,et al.  Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.

[64]  M. Taniwaki,et al.  International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome , 2001, British journal of haematology.

[65]  D. Christiansen,et al.  Mutations with loss of heterozygosity of p53 are common in therapy-related myelodysplasia and acute myeloid leukemia after exposure to alkylating agents and significantly associated with deletion or loss of 5q, a complex karyotype, and a poor prognosis. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  S. E. Jacobsen,et al.  Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for involvement at the hematopoietic stem cell level. , 2000, Blood.

[67]  P. Haslett,et al.  Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. , 1999, Journal of immunology.

[68]  R. D'Agostino.  Adjustment Methods: Propensity Score Methods for Bias Reduction in the Comparison of a Treatment to a Non‐Randomized Control Group , 2005 .

[69]  R. Larson,et al.  Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. , 1996, Blood.

[70]  H. Kaneko,et al.  TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities. , 1995, Blood.